VEGFA and age-related macular degeneration: However, currently, the therapeutic strategy for AMD and DR predominantly focusing on anti-neovascularization and reducing permeabilization of abnormal vascular with anti-vascular endothelial growth factor (VEGF) drugs, and though some anti-inflammation drugs are also in the clinical trials for treating AMD, the results are unsatisfactory.